Pfizer Inc. (NYSE:PFE) Shares Sold by Canandaigua National Bank & Trust Co.

Canandaigua National Bank & Trust Co. trimmed its stake in shares of Pfizer Inc. (NYSE:PFE) by 7.3% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 191,178 shares of the biopharmaceutical company’s stock after selling 15,035 shares during the period. Canandaigua National Bank & Trust Co.’s holdings in Pfizer were worth $5,305,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. GoalVest Advisory LLC lifted its position in shares of Pfizer by 304.9% during the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 811 shares during the period. Creekmur Asset Management LLC acquired a new position in shares of Pfizer during the 4th quarter worth approximately $32,000. VisionPoint Advisory Group LLC raised its position in shares of Pfizer by 52,350.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 1,047 shares during the last quarter. Tennessee Valley Asset Management Partners acquired a new position in shares of Pfizer during the 4th quarter worth approximately $36,000. Finally, DiNuzzo Private Wealth Inc. acquired a new position in shares of Pfizer during the 4th quarter worth approximately $37,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. BMO Capital Markets restated an “outperform” rating and set a $36.00 price objective (up from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Guggenheim started coverage on shares of Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research note on Monday. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Finally, Morgan Stanley boosted their price objective on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research note on Thursday, May 2nd. Ten equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $35.86.

Pfizer Trading Up 1.6 %

Shares of NYSE:PFE opened at $27.41 on Wednesday. The company has a quick ratio of 0.78, a current ratio of 1.05 and a debt-to-equity ratio of 0.66. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $39.87. The firm has a 50-day simple moving average of $27.58 and a 200 day simple moving average of $27.73.

Pfizer (NYSE:PFE) last posted its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, topping the consensus estimate of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The firm had revenue of $14.88 billion during the quarter, compared to analysts’ expectations of $13.87 billion. During the same quarter in the prior year, the firm earned $1.23 EPS. Pfizer’s quarterly revenue was down 19.5% on a year-over-year basis. On average, sell-side analysts predict that Pfizer Inc. will post 2.38 EPS for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, June 14th. Investors of record on Friday, May 10th were paid a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a yield of 6.13%. The ex-dividend date of this dividend was Thursday, May 9th. Pfizer’s dividend payout ratio is presently -2,799.53%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.